Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Innate lymphoid cells (ILCs) in mice are a family of antigen receptor-negative lymphocytes that play a crucial role in the innate immune response at mucosal surfaces and tissues. These cells, derived from common lymphoid progenitors, are divided into several groups: natural killer (NK) cells, ILC1, ILC2, ILC3, and lymphoid tissue inducer (LTi) cells. ILCs contribute to tissue homeostasis, immunity against pathogens, regulation of inflammation, and formation of lymphoid structures. Unlike T and B lymphocytes, ILCs lack rearranged antigen receptors and are defined by their ability to secrete cytokines rapidly. Dysregulation of ILCs is implicated in multiple diseases, including cancer, autoimmunity, inflammation, allergy, and infection. The term “mouse lymphoid cell” is not a defined molecular target but refers broadly to these diverse immune cell populations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Innate lymphoid cell (mouse) (ILC).